-
Analysts Weigh In On Gilead-Kite Pharma Deal
Tuesday, August 29, 2017 - 12:07pm | 762Read More...The big news for the week in the biotech space is the huge $12 billion buyout of Kite Pharma Inc (NASDAQ: KITE) by Gilead Sciences, Inc. (NASDAQ: GILD). Gilead, Kite and other biotech investors are eager to know Wall Street’s take on the big deal and what it means for the market. Related Link...
-
The Risk/Reward Potential For Exelixis Has Balanced As Catalysts Loom
Thursday, August 3, 2017 - 2:41pm | 310Read More...Deutsche Bank analyst Andrew Peters downgraded shares of Exelixis, Inc (NASDAQ: EXEL) on Thursday, while raising his price target from $26 to $29. The company had been Deutsche Bank’s top pick since initiating coverage on the biotech sector last year. The downgrade wasn't a result of...
-
Deutsche Bank's Take On Big Pharma: 3 Buys And A Hold
Friday, June 23, 2017 - 9:54am | 524Read More...Biotech stocks have been on a tear in the past week, with the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) up 8.8 percent. However, despite the run-up, Deutsche Bank sees more upside ahead for three of the biggest biotech names in the market. Analyst Andrew Peters initiated coverage on a...
-
Is Big Pharma Hinting At A SMID-Cap Biotech Rally?
Wednesday, February 3, 2016 - 2:16pm | 272Read More...UBS analyst Andrew Peters believes investors may be missing a strong bullish sign in the biotech sector this earnings season. According to Peters, the pullback in biotech stocks in recent months has made many smaller names compelling buyout targets, and big pharma earnings commentary seems to...
-
Prothena Shares Initiated With Buy At UBS
Friday, May 29, 2015 - 9:25am | 213Read More...In a report published Friday, UBS analyst Andrew Peters initiated coverage of Prothena Corporation PLC (NASDAQ: PRTA) with a Buy rating and $58 price target, following an analysis of the company' lead drug programs. "We believe early data for NEOD001 are clearly suggestive of an active...
-
UPDATE: UBS Securities Reiterates On BioMarin Pharmaceutical On Path To Long-Term Upside
Thursday, December 11, 2014 - 11:04am | 186Read More...In a report published Thursday, UBS Securities analyst Andrew Peters reiterated a Buy rating on BioMarin Pharmaceutical (NASDAQ: BMRN), and raised the price target from $87.00 to $112.00. In the report, UBS Securities noted, “We see BioMarin as a top pick in biotech heading into 2015, with a well-...
-
UBS Says Sunesis Leukemia Pivotal Trial Success 'Likely'
Wednesday, August 27, 2014 - 4:05pm | 185Read More...Sunesis Pharmaceuticals (NASDAQ: SNSS) gained 10 percent Wednesday to near a year high after an analyst said success is "more likely than not" for the company's development drug for leukemia. With key data from a Phase III pivotal trial expected in coming weeks, UBS' Andrew...
